Samsrita Labs Ltd
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
- Market Cap ₹ 24.2 Cr.
- Current Price ₹ 10.6
- High / Low ₹ 26.0 / 10.6
- Stock P/E
- Book Value ₹ 5.16
- Dividend Yield 0.00 %
- ROCE -62.4 %
- ROE -68.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 25.4%
- Company has a low return on equity of -23.9% over last 3 years.
- Company has high debtors of 365 days.
- Promoter holding has decreased over last 3 years: -27.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.28 | 0.58 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.02 | |
| 1.86 | 1.71 | 4.34 | 3.62 | 0.92 | 0.43 | 1.01 | 0.25 | 0.26 | 8.73 | |
| Operating Profit | -0.58 | -1.13 | -2.44 | -2.19 | -0.91 | -0.41 | -0.99 | -0.25 | -0.26 | -8.71 |
| OPM % | -45.31% | -194.83% | -128.42% | -153.15% | -9,100.00% | -2,050.00% | -4,950.00% | -43,550.00% | ||
| 0.01 | 0.03 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | 0.00 | 0.00 | 0.03 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.58 | -1.11 | -2.36 | -2.06 | -0.77 | 1.49 | -0.70 | -0.25 | -0.26 | -8.68 |
| Tax % | 124.14% | -5.41% | -1.27% | -3.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| -1.31 | -1.05 | -2.33 | -1.98 | -0.77 | 1.49 | -0.71 | -0.26 | -0.28 | -8.16 | |
| EPS in Rs | -1.28 | -0.89 | -1.69 | -1.34 | -0.52 | 1.01 | -0.48 | -0.18 | -0.19 | -3.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 0% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -2814% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -19% |
| 3 Years: | -14% |
| 1 Year: | -57% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -13% |
| 3 Years: | -24% |
| Last Year: | -69% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 22.75 |
| Reserves | -2.39 | -0.40 | -1.61 | -3.03 | -3.66 | -1.58 | -2.29 | -2.55 | -2.84 | -11.00 |
| 6.50 | 6.81 | 7.92 | 8.58 | 2.34 | 2.74 | 2.08 | 2.20 | 2.43 | 1.66 | |
| 4.88 | 4.73 | 6.11 | 7.85 | 3.09 | 1.16 | 0.96 | 1.09 | 1.17 | 0.98 | |
| Total Liabilities | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 | 14.39 |
| 0.46 | 0.36 | 0.26 | 0.13 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| CWIP | 14.85 | 16.13 | 17.77 | 18.99 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 | 2.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 4.22 | 4.80 | 4.80 | 4.79 | 4.76 | 9.84 |
| 3.93 | 6.40 | 8.19 | 9.08 | 9.08 | 9.06 | 7.49 | 7.49 | 7.55 | 2.55 | |
| Total Assets | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 | 14.39 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.26 | -3.32 | -2.96 | -1.05 | -0.34 | -0.40 | 0.66 | -0.13 | -0.23 | -4.26 | |
| -1.09 | -1.19 | -1.55 | -1.11 | -0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 3.26 | |
| 1.27 | 4.83 | 4.19 | 2.17 | 0.55 | 0.40 | -0.67 | 0.13 | 0.22 | 2.63 | |
| Net Cash Flow | -0.08 | 0.32 | -0.32 | 0.01 | -0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 1.63 |
| Free Cash Flow | -0.26 | -4.51 | -4.51 | -2.16 | -0.57 | -0.40 | 0.66 | -0.13 | -0.23 | -1.00 |
| CFO/OP | 45% | 294% | 121% | 48% | 37% | 98% | -67% | 52% | 88% | 49% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | 365.00 | ||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | ||||||||||
| Cash Conversion Cycle | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | 365.00 | ||
| Working Capital Days | -1,114.96 | -2,259.22 | -787.63 | -1,462.55 | 60,590.00 | 58,765.00 | 46,172.50 | -29,747.50 | ||
| ROCE % | -5.44% | -10.11% | -8.45% | -4.07% | 10.12% | -4.58% | -1.72% | -1.80% | -62.42% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Employees on Rolls count ・Standalone data |
|
||||||||
| Number of Granted Patents (Krisani Bio Sciences) count ・Standalone data |
|||||||||
| Number of Diagnostic Test Types Offered count ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Jul - Intimation of Newspaper Publication of 30th Annual General Meeting for the F.Y 2026-27
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Jul - Intimation of newspaper Publication of 30th Annual General Meeting for the F.Y 2026-27
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Jul - Newspaper advertisement regarding 30th Annual General Meeting.
- Reg. 34 (1) Annual Report. 18 Jul
- Notice Of AGM For The FY 2025-26 Scheduled To Be Held On 10.08.2026 18 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Products & R&D[1]
1. Stem Cell R&D: Focuses on regenerative medicine, stem cell therapies, bioengineered organs, nanobiotechnology, and advanced research for chronic and end-stage diseases. Published 250+ international papers and holds 2 patents.
2. New Drug Discovery: Develops IP-protected drug candidates for orphan and specialty diseases, with 11 international patents and a focus on the USFDA 505(b)(2) pathway.
3. RNA Interference: Develops miRNA-based biomarkers and molecular diagnostic kits, with a focus on patented diagnostic technologies.
4. Molecular Biomarkers
5. Medical Devices: Develops advanced medical devices, including extracorporeal support systems, implantable devices, CTC removal technologies, and nanotechnology-based treatment platforms.